COIN ripping today on the US perps news+7% to $380 and a new ATH https://t.co/KasgyAsj1d ...

Core Insights - The tobacco sector in 2025 presents two main investment options: Altria Group, Inc. and Philip Morris International Inc., each with distinct strategies and market focuses [1][2] Philip Morris Overview - Philip Morris is leading the transition to reduced-risk products (RRPs) with its flagship product IQOS, which has gained significant traction in international markets, contributing to volume growth and solidifying its leadership in the global RRP segment [3][4] - The acquisition of Swedish Match in 2022 expanded Philip Morris's smoke-free portfolio, with smoke-free products accounting for 42% of total revenues and 44% of gross profit in Q1 2025, reflecting a 15% year-over-year revenue growth in this segment [4][5] - Despite a focus on RRPs, Philip Morris also reported a 3.8% organic revenue growth in its traditional tobacco segment, demonstrating a balanced strategy between legacy products and innovation [5] Altria Overview - Altria has shown resilience against declining cigarette volumes through strong pricing power, with projected adjusted earnings per share for 2025 ranging from $5.30 to $5.45, indicating up to 5% year-over-year growth [10][12] - The company is making progress in the smoke-free market with its on! nicotine pouch product, which saw an 18% year-over-year shipment growth in Q1 2025, capturing significant market share despite higher retail prices [11] - Altria's recent acquisition of NJOY aims to strengthen its position in the e-vapor category, with plans for a relaunch focused on regulatory compliance and product quality [12][13] Valuation and Performance Comparison - Philip Morris trades at a forward P/E of 22.76x, reflecting a premium valuation due to its global presence and smoke-free momentum, while Altria trades at a lower multiple of 10.79x, appealing to value-focused investors [15] - Over the past year, Philip Morris has achieved a 76.1% stock gain, significantly outperforming Altria's 27.1% and the S&P 500's 10.8% return, indicating strong investor confidence in Philip Morris [17] Investor Considerations - Philip Morris is recognized for its leadership in RRPs and innovation, but its success may be largely priced in, with potential regulatory and currency risks [18] - Altria, while facing challenges in cigarette volumes, presents a compelling value proposition with lower valuation metrics and growth potential in smoke-free products and the vapor category [18]

People who have kids do need to have 3 kids to make up for those who have 0 or 1 kid or population will collapseMario Nawfal (@MarioNawfal):HUMANS NEED 2.7 KIDS PER WOMAN TO SURVIVE... WE'RE NOT EVEN CLOSEScientists now say 2.1 kids per woman won’t cut it - 2.7 is the real number needed to avoid long-term extinction.Right now, the U.S. is at 1.66, and most rich countries are even lower, including Italy at 1.29 https://t.co/FF4Y9pVVRd ...

RT Wall Street Mav (@WallStreetMav)Japan population is collapsing. The country has more deaths than births with its fertility rate below replacement levels.They need to start making more babies in Japan.Which policies are need to turn this around? https://t.co/VKhs6GSsXC ...

You're not bullish enough on this industry and the capacity required to meet global demand.HyperCORE is doing a ~10k TPS with ~5% CEX volume numbers and no tradfi assets.MegaETH is targeting 100k TPS because it will be needed. IBRL is a mindset.https://t.co/6oxGvLGTut ...

We're just a week away from the White House's uh self-imposed July 4th deadline to pass President Trump's mega bill. But even if it passes the Senate this week, the version they're sending back to the House is getting push back from some Republicans joining us now, Republican Congressman Chip Roy. Uh and you've made some some strong uh cases in the past on how you feel and you feel strongly congressman.Is is the Senate version in from what you know uh a a better do you like it more than than what the House ...

2017 Fourth Quarter and Year-End Earnings Conference Call NYSE: AWK NYSE: AWK Forward-Looking Statements Ed Vallejo Vice President, Investor Relations NYSE: AWK NYSE: AWK www.amwater.com 2 Forward-Looking Statements Certain statements in this presentation including, without limitation, 2018 earnings guidance, projected long-term earnings and dividend growth, our projected operation & maintenance efficiency ratio, the outcome of pending acquisition activity and estimated revenues from rate cases and other go ...

Group 1: Public Fund Market - The total scale of public funds in China reached 33.74 trillion yuan as of May 2025, marking the eighth historical high since early 2024 [1] - In May, the scale of money market funds increased by over 400 billion yuan, while bond funds grew by over 220 billion yuan [1] - The number of newly registered private funds in May 2025 was 1,219, with a total new registration scale of 607.26 billion yuan [1] Group 2: Banking Sector Changes - Many national banks have stopped offering medium to long-term large-denomination certificates of deposit due to reduced interest rate advantages [2] - This shift reflects a strategic adjustment in banks' cost control and liquidity management in response to pressure on net interest margins [2] Group 3: Semiconductor Industry Growth - The global semiconductor manufacturing industry is expected to maintain strong momentum, with monthly production capacity projected to reach 11.1 million wafers by 2028, growing at a CAGR of 7% [3] - Advanced process capacity (7nm and below) is expected to grow approximately 69%, from 850,000 wafers per month in 2024 to a historical high of 1.4 million wafers per month by 2028 [3] Group 4: New Technology Developments - The launch of the new generation of domestic general-purpose processor, Longxin 3C6000, was announced, which does not rely on foreign technology or supply chains [4] - This processor is designed to meet various computing needs across multiple scenarios, indicating advancements in China's tech capabilities [4] Group 5: Corporate Developments - Tianfeng International has upgraded its securities trading license to provide virtual asset trading services in Hong Kong [6] - Longjian Co. won a bid for a national road project valued at 780 million yuan, with a planned construction period of 48 months [8] - Anqi Yeast plans to invest 502 million yuan in a bio-manufacturing center, expected to be completed by the second half of 2027 [10]

Group 1 - The core viewpoint of the article highlights the significant rise of the innovative drug sector, with the Hang Seng Innovative Drug Index increasing by 55.61% year-to-date, outperforming the Hang Seng Index's 17.30% growth [1] - The innovative drug industry is transitioning from experience-based competition to technology-driven competition, positioning itself as a "tech-like" asset [1][2] - The trend of Chinese innovative drugs going global is irreversible and expected to strengthen, with a focus on whether Chinese companies can outperform their overseas counterparts in new target selection [2][6] Group 2 - The current price-to-sales (PS) valuation of innovative drugs is around 4 times, which is considered neutral in the context of asset scarcity, indicating potential for continued stock price increases as clinical data and business development improve [2][7] - The innovative drug market is characterized by high unmet medical needs, particularly in areas with few available treatment options, which presents opportunities for the development of blockbuster drugs [3][8] - The "double 10" rule in new drug development indicates an average development cycle of 10 years and costs exceeding $1 billion, highlighting the high-risk nature of the industry [4] Group 3 - China's innovative drug sector has made significant progress, with over 50% contribution to the top 20 global drug targets and surpassing Europe in original drug numbers as of 2021 [5][6] - The competition landscape is evolving into a scenario where both China and the U.S. are advancing in the innovative drug sector, with increased global competitiveness for Chinese companies [6] - The innovative drug sector is expected to continue its strong performance, driven by its alignment with current market trends and the recovery of valuations after years of pressure [7][8] Group 4 - Specific areas with strong potential for new drug development include antibody-drug conjugates (ADCs), GLP-1 metabolic disease drugs, and gene therapy for rare diseases [8] - For investors looking to enter the innovative drug market, a systematic investment approach through funds is recommended due to the high barriers and complexities involved in the sector [9]

Market Performance - As of June 26, the DRG/DIP concept index rose by 1.97%, ranking fifth among concept sectors, with 16 stocks increasing in value [1] - Notable gainers included Kechuang Information, which hit a 20% limit up, and Huayu Software, Guoxin Health, and Digital Certification, which rose by 4.75%, 3.69%, and 3.50% respectively [1] - The sectors with the highest and lowest daily performance included the Military Equipment Restructuring concept at +8.73% and the Photolithography Machine concept at -1.48% [1] Capital Flow - The DRG/DIP concept sector saw a net inflow of 412 million yuan, with 14 stocks receiving net inflows, and 5 stocks attracting over 30 million yuan each [1] - Kechuang Information led the net inflow with 205 million yuan, followed by Guoxin Health, Huayu Software, and Digital Certification with net inflows of 69.67 million yuan, 64.82 million yuan, and 47.87 million yuan respectively [1] - The top three stocks by net inflow ratio were Kechuang Information at 20.10%, Guoxin Health at 13.05%, and Huayu Software at 11.15% [2]